Sonde Health, a Boston, MA-based health technology company, raised $19.25M in Series B funding.
The round was led by Partners Investment, with participation from NEOM Company, KT Corporation, PureTech Health and M Ventures. Partners Investment Vice President Joonsoo Kim will join Sonde’s board of directors.
The company intends to use the funds to accelerate its commercial growth, expand its platform into new health conditions, and enter new geographies.
Led by CEO David Liu, Sonde provides voice-based health monitoring solutions serving health companies, providers, pharma, and device OEMs through its vocal biomarker platform. Leveraging a voice data set with over 1.2 million samples from 85,000+ individuals on 4 continents, Sonde uses audio signal processing, speech science, and AI/machine learning to sense and analyze subtle vocal changes due to changes in a person’s physiology to provide key insights into health and well-being.
Today, the company provides its enterprise vocal biomarker technology to companies across several health verticals, including telehealth, pharmaceutical, remote patient monitoring, and consumer/medical devices.
GN Group will integrate Sonde’s Mental Fitness vocal biomarker into its hearing products. The company is already working with Sonde to develop an MCI vocal biomarker. Qualcomm, which has already integrated Sonde’s vocal biomarkers into its mobile device chipsets, has extended the relationship to include its wearable chipsets. Koye Pharmaceuticals, which had already engaged Sonde to develop a COPD vocal biomarker, has expanded the partnership to develop a novel mental health vocal biomarker for deployment in India.
FinSMEs
09/12/2022